2 sources checked · 2 source groups included · 7m ago
Still Watching
CNA Explains: What we know about the Moderna, Merck breakthrough cancer vaccine
International Business Times and CNA Singapore describe the same event in different terms.
1 Left1 Center0 Right
Still watching.Optics is waiting for a cleaner match before calling the split.
STILL WATCHING
As of August 21, 2026 at 11:30 AM, this is how Optics News reads the wording differences in this story.
What happenedThe personalised vaccine has succeeded in a final-stage melanoma trial. Here’s how it works, when it could become available and why researchers hope the approach can be used against other cancers.
The headline splitThe left frames it as "Moderna, Merck's Cancer Vaccine Breakthrough Raises Hope For New Wave Of Personalized Tre...". The center frames it as "CNA Explains: What we know about the Moderna, Merck breakthrough cancer vaccine".
Match confidenceDeveloping. The source map is still developing. Keep watching for more sources to join.
Same-event confidenceDeveloping
Not enough sources yet to confirm this is the same specific event.
Framing confidenceHidden
Wording-gap score hidden — source map is too narrow to read confidently.
WHAT EACH SIDE EMPHASIZED
Left / center-leftModerna, Merck's Cancer Vaccine Breakthrough Raises Hope For New Wave Of Personalized Treatments
International Business Times · Center-left · News report
CenterCNA Explains: What we know about the Moderna, Merck breakthrough cancer vaccine
CNA Singapore · Center · News report
Right / center-rightNo matching source in this bucket yet.
CNA Explains: What we know about the Moderna, Merck breakthrough cancer vaccine
The personalised vaccine has succeeded in a final-stage melanoma trial. Here’s how it works, when it could become available and why researchers hope the approach can be used against other c...
Moderna, Merck's Cancer Vaccine Breakthrough Raises Hope For New Wave Of Personalized Treatments
Moderna and Merck's experimental cancer vaccine has delivered positive results in a late-stage melanoma trial, giving a major boost to personalized m RNA treatments as rivals including Bio...
